X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

New Research Projects For Growth From The Office of The FDA

Content Team by Content Team
20th April 2023
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

In 2018, the FDA’s Centre for Drug Evaluation and Research’s Office of New Drugs- OND went on to develop a new programme so as to centralise as well as enhance the regulatory science research actions. More recently, the OND research programme went on to publish its first two fiscal year annual reports, and there happen to be significant projects that are looking to aid in improving the research outcomes across patient populations.

The associate director of the OND-RP, Laura Jaeger, PhD, mentions in an interaction how most project ideas arise from the scientific review staff of the OND, who analyse and evaluate the safety of the drug and the efficacy of the profile in order to help decide if the treatment has to be approved. She says that the OND reviewers also evaluate if more measures are required for the safe usage of the drug or if certain patient populations shouldn’t take the medication, besides other regulatory decisions.

When it comes to how OND-RP funds regulatory science research against other kinds of research, Jaeger says that the programme is aimed at addressing certain scientific questions that will go on to produce immediate impacts concerning how CDER and FDA would make decisions related to the approval of drugs. These projects happen to be shorter as compared to basic scientific research, with a timeline ranging between three and four years.

There are two ways that OND-RP goes about funding the research: intramurally and extramurally. When it comes to the extramural end, Jaeger goes on to say that there are several mechanisms that fund the research, such as the FDA’s broad agency announcement programme as well as its centre for excellence in regulatory science and innovation. They also make use of agreements such as memorandum of understanding (MoU), research collaborations, and cooperative research and development agreements so as to formalise their research partnerships. On the other hand, when we talk of intramural research, it primarily takes place through the Oak Ridge Institute of Science and Education Fellowship Programme, wherein college students as well as recent graduates can go on to conduct the research under the guidance of an FDA mentor when it comes to a regulatory science project.

An instance of the OND-RP-funded project when it comes to the extramural report is the push to develop blood-based biomarkers or even molecules that give out a signal of a normal or abnormal biologic process in the case of a traumatic brain injury. Drug development in this area happens to be difficult because the symptoms of individuals vary and there are few objective ways to gauge the prognosis. A biomarker will go on to help the investigators sort individuals in clinical trials by way of disease severity, ultimately pushing drug development. The ORISE report focuses primarily on enhancing the bulk drug substance evaluation and how compounders make use of these substances to make customised drugs for specific patients.

In scenario that a patient has an allergy to an ingredient in a drug that is FDA-approved, compounders can go on to use bulk drug substances to compound the drug without the allergen. In this project, the ORISE fellows aided to create internal resources to streamline review of bulk substances.

Previous Post

Reimagining Pharma Supply Chain in a Multi-Tier Supplier Ecosystem

Next Post

Singapore Creates Ingestible Capsule For Radiation Track

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Singapore Creates Ingestible Capsule For Radiation Track

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In